• Login
    View Item 
    •   Home
    • Hospital Research
    • Leinster
    • St. James's Hospital
    • View Item
    •   Home
    • Hospital Research
    • Leinster
    • St. James's Hospital
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Map of Submissions

    Home Page
    UlsterN
    4708
    UlsterS
    4708
    Connacht
    1607
    Munster
    48
    Leinster
    426

    Browse

    All of Lenus, The Irish Health RepositoryCommunitiesTitleAuthorsDate publishedSubjectsThis CollectionTitleAuthorsDate publishedSubjects

    My Account

    LoginRegister

    About

    About LenusDirectory of Open Access JournalsOpen Access Publishing GuideNational Health Library & Knowledge ServiceGuide to Publishers' PoliciesFAQsTerms and ConditionsVision StatementRIAN Pathways to Irish ResearchHSE position statement on Open AccessNational Open Research Forum (NORF)Zenodo (European Open Research repository)

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Sequist, Lecia V
    Yang, James Chih-Hsin
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Mok, Tony
    Geater, Sarayut Lucien
    Orlov, Sergey
    Tsai, Chun-Ming
    Boyer, Michael
    Su, Wu-Chou
    Bennouna, Jaafar
    Kato, Terufumi
    Gorbunova, Vera
    Lee, Ki Hyeong
    Shah, Riyaz
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Schuler, Martin
    Show allShow less
    Affiliation
    Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
    Issue Date
    2013-09-20
    Keywords
    LUNG CANCER
    CHEMOTHERAPY
    MeSH
    Adenocarcinoma
    Adult
    Aged
    Aged, 80 and over
    Antineoplastic Combined Chemotherapy Protocols
    Cisplatin
    Female
    Glutamates
    Guanine
    Humans
    Lung Neoplasms
    Male
    Middle Aged
    Mutation
    Neoplasm Metastasis
    Quinazolines
    Receptor, Epidermal Growth Factor
    Show allShow less
    
    Metadata
    Show full item record
    Citation
    Sequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, 31 (27):3327-34 J. Clin. Oncol.
    Journal
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    URI
    http://hdl.handle.net/10147/323888
    DOI
    10.1200/JCO.2012.44.2806
    PubMed ID
    23816960
    Abstract
    The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
    Item Type
    Article
    Language
    en
    ISSN
    1527-7755
    ae974a485f413a2113503eed53cd6c53
    10.1200/JCO.2012.44.2806
    Scopus Count
    Collections
    St. James's Hospital

    entitlement

    Related articles

    • Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    • Authors: Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV
    • Issue date: 2013 Sep 20
    • Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
    • Authors: Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N
    • Issue date: 2015 Sep
    • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
    • Authors: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV
    • Issue date: 2015 Feb
    • [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    • Authors: Sárosi V, Balikó Z
    • Issue date: 2014 Dec
    • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    • Authors: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL
    • Issue date: 2014 Feb
    National Health Library & Knowledge Service | Health Service Executive | Dr Steevens' Hospital | Dublin 8 | Ireland
    lenus@hse.ie | Tel +353 (1) 6352558
    DSpace software copyright © 2002-2017  DuraSpace
    Contact Us | Disclaimer
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.